Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 11-20 of 182 (Search time: 0.006 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2016ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatmentEadie, L.; Hughes, T.; White, D.; New Directions in Leukaemia Research 2016 Meeting (NDLR) (16 Mar 2016 - 19 Mar 2016 : Noosa, QLD)
2004Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemiaMollee, P.; Arthur, C.; Hughes, T.; Januszewicz, H.; Grigg, A.; Bradstock, K.; Wolf, M.; Gibson, J.; Schwarer, A.; Spencer, A.; Browett, P.; Hawkins, T.; Seldon, M.; Herrmann, R.; Watson, A.; Seymour, J.; Martin, N.; Shina, S.; Low, C.; Wright, S.; et al.
2003Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRHui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
2007BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteriaBranford, S.; Seymour, J.; Grigg, A.; Arthur, C.; Rudzki, Z.; Lynch, K.; Hughes, T.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaDruker, B.; Guilhot, F.; O'Brien, S.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.; Silver, R.; Goldman, J.; Stone, R.; Cervantes, F.; Hochhaus, A.; Powell, B.; Gabrilove, J.; Rousselot, P.; Reiffers, J.; Cornelissen, J.; Hughes, T.; Agis, H.; Fischer, T.; et al.
2010Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemiaSaglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
2017CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressorsHughes, A.; Clarson, J.; Tang, C.; Vidovic, L.; White, D.; Hughes, T.; Yong, A.
2011Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialKantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
2012Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLarson, R.; Hochhaus, A.; Hughes, T.; Clark, R.; Etienne, G.; Kim, D.; Flinn, I.; Kurokawa, M.; Moiraghi, B.; Yu, R.; Blakesley, R.; Gallagher, N.; Saglio, G.; Kantarjian, H.